An interventional study of Pitavastatin 1 mg daily or 4 mg daily in Coronary Artery Disease, sponsored by Juntendo University. Completed at 2 sites in Japan. Open to participants aged 20 Years to 79 Years. Per ClinicalTrials.gov, last updated 2021-05-17.
Sponsored by Juntendo University · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 134 studies in Coronary Artery Disease with a site in Japan — 12 open to participants now, 21 under way, 2 of them phase 3. Coronary Artery Disease · Japan.
Among the 134 studies in Coronary Artery Disease with a site in Japan, this one is the 5th largest by enrollment of the 100 interventional ones that give a count, is one of 19 that started in 2010, is one of 39 with no phase, and was the 21st registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →12 of the 134 studies in Coronary Artery Disease with a site in Japan are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Japan, United States, Australia and 2 more countries
Ages 18–80
Medtronic Vascular · Sites in Japan, United States, Canada and 6 more countries
Ages 18+
CSL Behring · Sites in Japan, United States, Argentina and 32 more countries
Ages 18+
Seung-Jung Park · Sites in Japan, Hong Kong, India and 2 more countries
Ages 20+
Weill Medical College of Cornell University · Sites in Japan, United States, Australia and 23 more countries
Ages 18+ · Women only
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 20 Years to 79 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
134 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 9 · Phase 3 17 · Phase 4 36
First in 1996; this study’s year is marked. 19 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 13,054 is above the median of 123 across 3,011 interventional studies indexed under Coronary Artery Disease.
Median enrollment 445 across the 100 interventional studies, 431 across the 34 observational. Of the 91 that completed or were terminated, 36 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
64 of 134 have an industry lead sponsor. The 10 most frequent:
Juntendo University is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Juntendo University has 2 studies filed under Coronary Artery Disease — fewer than ten, so there is no comparison to draw.
4 of the studies in Coronary Artery Disease with a site in Japan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03820492Insel Gruppe AG, University Hospital BernComparison of Optical Coherence Tomography-derived Minimal Lumen Area, Invasive Fractional Flow Reserve and FFRCT | 2026-12-31 |
| NCT06535854Medtronic VascularPrevail Global Study | 2027-02 |
| NCT05829889Seung-Jung ParkFractional Flow Reserve Versus Angiography for Treatment-Decision and Evaluation of Significant Left MAIN Coronary Artery Disease | 2027-06 |
| NCT07830719Novartis PharmaceuticalsDose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRP | 2027-08-15 |
Add all 4 to your calendar (.ics) → With an account.
Among the 134 studies in Coronary Artery Disease with a site in Japan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the prevention of cardiovascular disease by moderate cholesterol lowering therapy, pitavastatin 1mg/day or aggressive cholesterol lowering therapy, pitavastatin 4mg/day in patients with stable coronary artery disease.
It was already demonstrated by previous clinical trials that statins lower the incidence of death and cardiovascular events in patients with coronary artery disease. However, whether aggressive cholesterol lowering therapy, using high dosage of statins, is more effective than moderate cholesterol lowering therapy for the prevention of cardiovascular events in patients with coronary artery disease has not been studied in Japan.
Inclusion Criteria:
Coronary artery disease patients meeting one of the following events
Hypercholesterolemia patients meeting one of following criteria
Exclusion Criteria:
Exclusion Criteria(Pre-Run-in period)
Patients who meet of LIVALO tablet below
Exclusion Criteria(Post-Run-in period)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Pitavastatin 1 mg daily or 4 mg daily
Drug: Pitavastatin 1 mg daily or 4 mg daily
Patients who met all inclusion criteria and did not meet exclusion criteria (1) are entered in run-in period, loading pitavastatin 1 mg/day for more than 1 month when informed consent was given. (Primary registration) After 1 month, patients who did not meet exclusion criteria(2) are randomized to take pitavastatin 1 mg/day or 4 mg/day.
Also known as: LIVALO Tablet
Occurrence of one of following events(Cardiovascular death, Non-fatal Myocardial Infarction (MI), Non-fatal Cerebral Infarction (CI), Unstable angina requiring urgent hospitalization)
Time frame: 3-6 years
Composite cardiovascular events
Time frame: 3-6 years
Composite coronary heart disease events
Time frame: 3-6 years
Composite cerebrovascular events
Time frame: 3-6 years
Death events
Time frame: 3-6 years
Heart disease events
Time frame: 3-6 years
Cerebrovascular events
Time frame: 3-6 years
The other events
Time frame: 3-6 years
Ran from Feb 2010 to primary completion in Jun 2016, 76 months.
Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's 76 months is above that.
Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pitavastatin
Juntendo University